Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.

[1]  L. Fisher,et al.  Relation between changes in ejection fraction over time and subsequent mortality and morbidity in Val-HeFT , 2003 .

[2]  J. Cohn.  Angiotensin receptor blockers and clinical trials in heart failure. , 2003, European heart journal.

[3]  P. Vandervoort,et al.  Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. , 2002, Journal of the American College of Cardiology.

[4]  R. Latini,et al.  Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT). , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[5]  K. Adams,et al.  Surrogate End Points in Heart Failure , 2002, The Annals of pharmacotherapy.

[6]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[7]  P. Hildebrandt,et al.  Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. , 2000, Journal of the American College of Cardiology.

[8]  M. Quiñones,et al.  Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. , 2000, Journal of the American College of Cardiology.

[9]  J. Cohn,et al.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.

[10]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[11]  J. Cohn,et al.  Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. , 1999, Journal of cardiac failure.

[12]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[13]  J. Cohn,et al.  Prognosis in congestive heart failure. , 1994, Journal of cardiac failure.

[14]  M. Quiñones,et al.  Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.

[15]  M. Kittleson.  Left ventricular function and failure. I , 1994 .

[16]  J. Sadoshima,et al.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro , 1993, Cell.

[17]  M. Packer,et al.  Role of surrogate end points in the evaluation of drugs for heart failure. , 1993, Journal of the American College of Cardiology.

[18]  J. Sadoshima,et al.  Critical Role of the AT1 Receptor Subtype , 2005 .

[19]  M. Rousseau,et al.  Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators. , 1993, Circulation.

[20]  F. Tristani,et al.  Ejection Fraction, Peak Exercise Oxygen Consumption, Cardiothoracic Ratio, Ventricular Arrhythmias, and Plasma Norepinephrine as Determinants of Prognosis in Heart Failure , 1993, Circulation.

[21]  Peter Gaudron,et al.  Progressive Left Ventricular Dysfunction and Remodeling After Myocardial Infarction Potential Mechanisms and Early Predictors , 1993, Circulation.

[22]  G. Booz,et al.  Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. , 1992, Annual review of physiology.

[23]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[24]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[25]  V. Dzau,et al.  Tissue Renin-Angiotensin Systems in the Pathophysiology of Heart Failure , 1990 .